Stalicla Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 5

Stalicla General Information

Description

Developer of an algorithm-based platform designed to identify subgroups of autism spectrum disorder patients. The company's tool identifies non-behavioral subgroups of patients with idiopathic autism spectrum disorder and corresponding first-in-class treatment candidates, enabling the healthcare industry to use robust sets of clinical signs and symptoms with big data analytics for effective and personalized treatment options.

Contact Information

Website
www.stalicla.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Campus Biotech Innovation Park
  • Avenue de Secheron 15
  • 1202 Geneva
  • Switzerland
+41 022
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • Campus Biotech Innovation Park
  • Avenue de Secheron 15
  • 1202 Geneva
  • Switzerland
+41 022

Stalicla Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Stalicla Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 01-Feb-2026 Completed Clinical Trials - Phase 2
8. Later Stage VC 30-Jun-2025 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B) 11-Apr-2024 Completed Clinical Trials - Phase 2
6. Later Stage VC 30-Jun-2022 Completed Clinical Trials - Phase 1
5. Early Stage VC 10-Dec-2021 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A2) 30-Jul-2021 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A1) 31-Jan-2018 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Stalicla’s complete valuation and funding history, request access »

Stalicla Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
Ordinary
Ordinary 284,415 $0.100000 $62.23 $62.23 1x $62.23 15.44%
Ordinary 381,066 $0.100000 $10.51 $10.51 1x $10.51 20.69%
To view Stalicla’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Stalicla Patents

  • 108

    Total Documents Applications and Grants

  • Total Patents Families

  • 43

    Granted

  • 31

    Pending

  • Expiring in next 12 mo

Stalicla Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2025202130-A1 Treatment for asd Inactive 25-Mar-2024
ES-3039490-R1 Treatment for asd Pending 25-Mar-2024
JP-2025165870-A Treatment for asd Inactive 25-Mar-2024
US-20250295641-A1 Treatment for asd Pending 25-Mar-2024
ES-3039490-A2 Treatment for asd (machine-translation by google translate, not legally binding) Pending 25-Mar-2024 A61K31/437
To view Stalicla’s complete patent history, request access »

Stalicla Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Stalicla Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Addex Therapeutics Corporation Minority
SPRIM Global Investments Holding Company Minority
YADAY Family Office Minority
LIFTT Venture Capital Minority
Akilia Partners Venture Capital Minority
To view Stalicla’s complete investors history, request access »

Stalicla Investments (1)

Stalicla’s most recent deal was a PIPE with TheraCryf for . The deal was made on 16-Jan-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
TheraCryf 16-Jan-2024 PIPE Biotechnology
To view Stalicla’s complete investments history, request access »

Ready to get started?

Request a free trial

Stalicla FAQs

  • When was Stalicla founded?

    Stalicla was founded in 2017.

  • Where is Stalicla headquartered?

    Stalicla is headquartered in Geneva, Switzerland.

  • What is the size of Stalicla?

    Stalicla has 23 total employees.

  • What industry is Stalicla in?

    Stalicla’s primary industry is Drug Discovery.

  • Is Stalicla a private or public company?

    Stalicla is a Private company.

  • What is Stalicla’s current revenue?

    The current revenue for Stalicla is .

  • How much funding has Stalicla raised over time?

    Stalicla has raised $56.7M.

  • Who are Stalicla’s investors?

    Addex Therapeutics, SPRIM Global Investments, YADAY, LIFTT, and Akilia Partners have invested in Stalicla.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process